MARKET

MTVA

MTVA

MetaVia Inc
NASDAQ
1.820
0.000
0.00%
Opening 10:42 02/09 EST
OPEN
1.820
PREV CLOSE
1.820
HIGH
1.890
LOW
1.820
VOLUME
27.27K
TURNOVER
--
52 WEEK HIGH
23.10
52 WEEK LOW
1.661
MARKET CAP
5.84M
P/E (TTM)
-0.1312
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MTVA last week (0202-0206)?
Weekly Report · 5h ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/6/26
TipRanks · 2d ago
Vanguard Total Stock Market ETF (VTI) Daily Update—2/5/26
TipRanks · 4d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/4/26
TipRanks · 5d ago
Metavia Provided an Update on Its Ongoing Collaboration With Syntekabio, Leveraging Deepmatcher Platform, Confirming Strong Inflammatory And Cardiometabolic Target Engagement, Supporting Development in MASH and Potential Type 2 Diabetes
Benzinga · 5d ago
MetaVia provides update on collaboration with Syntekabio
TipRanks · 5d ago
Metavia Collaborates with Syntekabio on AI-Driven Drug Discovery
Reuters · 5d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/3/26
TipRanks · 6d ago
More
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.

Webull offers MetaVia Inc stock information, including NASDAQ: MTVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MTVA stock methods without spending real money on the virtual paper trading platform.